Remove clinical medical-devices
article thumbnail

STAT+: Medicare official says breakthrough device reimbursement rule coming in early summer

STAT

WASHINGTON — A federal rule aiming to make reimbursement for breakthrough devices easier is slated for early summer, a Centers for Medicare and Medicaid Services official said on Thursday. The agency has faced intense pressure from device makers frustrated with the slow pace of Medicare reimbursement decisions.

Insurance 111
article thumbnail

FDA spends $1.2M on VR-enabled hub to spur development of at-home care devices

Fierce Healthcare

The Food & Drug Administration’s device center launched an initiative to promote at-home medical device development with a focus on health equity in at-home care. Medical devices and other innovations that make acute and on-going at-home clinical management possible are receiving a boost in attention from FDA.

FDA 65
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: Device made by company J&J is buying for $13 billion clears hurdle in independent study

STAT

A fully independent clinical trial researchers thought might disprove a cardiac device made by Shockwave Medical, the company that Johnson & Johnson is buying for $13 billion, ended up providing some support for the device’s utility. but was previously rejected by the U.S. Food and Drug Administration.

FDA 113
article thumbnail

FDA Releases Final Guidance on Use of Digital Health Technologies for Remote Data Acquisition in Clinical Investigations

The FDA Law Blog

Lenz, Principal Medical Device Regulation Expert & Lisa M. Baumhardt, Senior Medical Device Regulation Expert — As an end of the year gift, FDA finalized its guidance document, Digital Health Technologies for Remote Data Acquisition in Clinical Investigations , in late December. By Adrienne R.

FDA 105
article thumbnail

Medical device manufacturers must remain “vigilant” to ensure data integrity of premarket submissions

European Pharmaceutical Review

The US Food and Drug Administration (FDA) recently highlighted data integrity issues concerning premarket submissions received for medical devices. This was communicated in a Letter to Industry (medical devices) published by the agency on 20 February 2024.

FDA 88
article thumbnail

STAT+: FDA proposes changes to key approval pathway for medical devices, five years after promising

STAT

Five years after promising to fix a flawed regulatory pathway widely used by medical device manufacturers, the Food and Drug Administration has issued new guidelines to improve its so-called 510(k) program that has long been lambasted for letting risky devices fall through the cracks.

FDA 141
article thumbnail

STAT+: Drugs are still mostly tested in white men. Will the FDA change that next year?

STAT

WASHINGTON — Sometime next year drug and medical device companies will have to tell the Food and Drug Administration how they plan to include people of color in clinical trials. Congress in late 2022 passed a law requiring companies to give FDA their plans for diversifying clinical trials.

FDA 133